Associations between Biomarkers of Complement Activation, Galactose-Deficient IgA1 Antibody and the Updated Oxford Pathology Classification of IgA Nephropathy

被引:7
|
作者
Juan, Yun-Ting [1 ]
Chiang, Wen-Chih [2 ]
Lin, Wei-Chou [3 ]
Yang, Cheng-Wen [1 ]
Chou, San-Fang [4 ]
Hung, Ruo-Wei [1 ]
Chiu, Yen-Ling [1 ,4 ,5 ,6 ,7 ]
机构
[1] Far Eastern Mem Hosp, Dept Nephrol, New Taipei 220, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Med, Div Nephrol, Taipei 100, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan
[4] Far Eastern Mem Hosp, Dept Med Res, New Taipei 220, Taiwan
[5] Yuan Ze Univ, Grad Inst Med, Taoyuan 320, Taiwan
[6] Yuan Ze Univ, Grad Program Biomed Informat, Taoyuan 320, Taiwan
[7] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei 100, Taiwan
关键词
complement C5a; factor Ba; galactose-deficient IgA1; IgA nephropathy; Oxford classification;
D O I
10.3390/jcm11144231
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Our prior study indicates a close relationship between alternative complement pathway activation, galactose-deficient IgA1 (Gd-IgA1) concentration and clinical severity of IgA nephropathy (IgAN). Nonetheless, the relationship between complement factors and the updated Oxford classification of IgAN remains unclear. This study enrolled eighty-four previously untreated, biopsy-diagnosed IgAN patients. The clinical and laboratory findings were collected at the time of biopsy. Plasma levels of complement factor C5a, factor Ba and Gd-IgA1 were measured and analyzed. It was found that the levels of proteinuria positively correlated with the updated Oxford classification of mesangial hypercellularity (M), endocapillary hypercellularity (E), tubular atrophy/interstitial fibrosis (T) and crescents (C). In addition, plasma Gd-IgA1 titer was significantly elevated in IgAN patients with tubular atrophy/interstitial fibrosis (T). In separate multivariable logistic regression models, both Gd-IgA1 and factor Ba independently predict higher T scores. The results indicate that both the levels of Gd-IgA1 antibody and biomarkers of the alternative complement pathway activation reflect the Oxford classification of IgAN. Whether these biomarkers can be used to guide therapeutic decisions requires further study.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression
    Maixnerova, Dita
    Ling, Chunyan
    Hall, Stacy
    Reily, Colin
    Brown, Rhubell
    Neprasova, Michaela
    Suchanek, Miloslav
    Honsova, Eva
    Zima, Tomas
    Novak, Jan
    Tesar, Vladimir
    PLOS ONE, 2019, 14 (02):
  • [22] Clinical Significance of Serum Galactose-Deficient IgA1 Level in Children with IgA Nephropathy
    Irabu, Hitoshi
    Shimizu, Masaki
    Kaneko, Shuya
    Inoue, Natsumi
    Mizuta, Mao
    Ohta, Kazuhide
    Yachie, Akihiro
    JOURNAL OF IMMUNOLOGY RESEARCH, 2020, 2020
  • [23] Cellular Signaling and Production of Galactose-Deficient IgA1 in IgA Nephropathy, an Autoimmune Disease
    Reily, Colin
    Ueda, Hiroyuki
    Huang, Zhi-Qiang
    Mestecky, Jiri
    Julian, Bruce A.
    Willey, Christopher D.
    Novak, Jan
    JOURNAL OF IMMUNOLOGY RESEARCH, 2014, 2014
  • [24] Galactose-Deficient IgA1 in African Americans with IgA Nephropathy: Serum Levels and Heritability
    Hastings, M. Colleen
    Moldoveanu, Zina
    Julian, Bruce A.
    Novak, Jan
    Sanders, John T.
    McGlothan, Kim R.
    Gharavi, Ali G.
    Wyatt, Robert J.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (11): : 2069 - 2074
  • [25] Somatic Mutations Modulate Autoantibodies against Galactose-Deficient IgA1 in IgA Nephropathy
    Huang, Zhi Qiang
    Raska, Milan
    Stewart, Tyler J.
    Reily, Colin
    King, R. Glenn
    Crossman, David K.
    Crowley, Michael R.
    Hargett, Audra
    Zhang, Zhixin
    Suzuki, Hitoshi
    Hall, Stacy
    Wyatt, Robert J.
    Julian, Bruce A.
    Renfrow, Matthew B.
    Gharavi, Ali G.
    Novak, Jan
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 27 (11): : 3278 - 3284
  • [26] Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels
    Moldoveanu, Z.
    Wyatt, R. J.
    Lee, J. Y.
    Tomana, M.
    Julian, B. A.
    Mestecky, J.
    Huang, W-Q
    Anreddy, S. R.
    Hall, S.
    Hastings, M. C.
    Lau, K. K.
    Cook, W. J.
    Novak, J.
    KIDNEY INTERNATIONAL, 2007, 71 (11) : 1148 - 1154
  • [27] Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy
    Wada, Yukihiro
    Matsumoto, Kei
    Suzuki, Taihei
    Saito, Tomohiro
    Kanazawa, Nobuhiro
    Tachibana, Shohei
    Iseri, Ken
    Sugiyama, Motonori
    Iyoda, Masayuki
    Shibata, Takanori
    PLOS ONE, 2018, 13 (11):
  • [28] CLINICAL SIGNIFICANCE OF SERUM AND MESANGIAL GALACTOSE-DEFICIENT IGA1 IN PATIENTS WITH IGA NEPHROPATHY
    Wada, Yukihiro
    Matsumoto, Kei
    Suzuki, Taihei
    Saito, Tomohiro
    Kanazawa, Nobuhiro
    Tachibana, Shohei
    Fukuda, Kei
    Iseri, Ken
    Iyoda, Masayuki
    Shibata, Takanori
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [29] Serum Galactose-Deficient IgA1 Level Is Not Associated with Proteinuria in Children with IgA Nephropathy
    Hastings, M. Colleen
    Afshan, Sabahat
    Sanders, John T.
    Kane, Oulimata
    Eison, T. Matthew
    Lau, Keith K.
    Moldoveanu, Zina
    Julian, Bruce A.
    Novak, Jan
    Wyatt, Robert J.
    INTERNATIONAL JOURNAL OF NEPHROLOGY, 2012, 2012
  • [30] In Vivo Evidence of Complement Requirement for Mesangioproliferative Activity of Immune Complexes Containing Galactose-Deficient IgA1 in IgA Nephropathy
    Moldoveanu, Zina
    Hall, Stacy D.
    Gurganus, Graham
    Novak, Lea
    Huang, Zhi Qiang
    Qiu Shihong
    Green, Todd J.
    Novak, Jan
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):